



Amendments to the Claims

1. (Currently amended) A ~~fused bicyclic pyrimidine derivative represented by the following general compound of formula (1), or a salt thereof:~~




wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) ~~that~~ ring selected from the group consisting of



are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆ alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms;

m is 1 or 2; and

n is 2 or 3.

2. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 1 represented by the following general formula (1a), or a salt thereof:




wherein the ring A is a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a C₁ to C₆ alkyl group, which may be substituted with a halogen atom, and a C₁ to C₆ alkoxy group;

the ring C is a 5- to 7-membered nitrogen-containing ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom;

the ring C may further contain a substituent selected from the group consisting of a C₁ to C₆ alkyl group, a hydroxyl group, a C₁ to C₆ alkoxy group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group, a C₁ to C₆ alkylsulfonyl group, an amino group, a mono- or di-substituted C₁ to C₆ alkylamino group, a C₁ to C₆ alkylcarbonylamino group, a C₁ to C₆ alkoxy carbonylamino group, a C₁ to C₆


alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, and a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms; and

n is 2 or 3.

3. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 2, or a salt thereof, wherein in the ~~general~~ formula (1a), the ring C is represented either by the following formula:




wherein R¹ is a hydroxyl group, a C1 to C6 alkoxy group, a formyl group, a C1 to C6 alkylcarbonyl group, a C1 to C6 alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C1 to C6 alkylcarbamoyl group, an amino group, a mono- or di-substituted C1 to C6 alkylamino group, a C1 to C6 alkylcarbonylamino group, a C1 to C6 alkoxy carbonylamino group, a C1 to C6 alkylsulfonylamino group, an oxo group, a 6-membered aromatic heterocyclic group, or a substituent represented by the following formula:




wherein the ring D is a 3- to 7-membered nonaromatic heterocyclic ring, which may contain, aside from the nitrogen atom, 1 to 3 heteroatoms selected from the group consisting of a nitrogen atom, a sulfur atom, and an oxygen atom and may further contain 1 or 2 oxo-substituted carbon atoms.

4. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 2, or a salt thereof, wherein in the ~~general~~-formula (1a), the ring C is represented by the following formula:




wherein X is -O- or -S(O)_q-; and q is 0, 1, or 2.

5. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 2, or a salt thereof, wherein in the ~~general~~-formula (1a), the ring C is a functional group represented by the following formula:




wherein R² is a hydrogen atom, a C₁ to C₆ alkyl group, a formyl group, a C₁ to C₆ alkylcarbonyl group, a C₁ to C₆ alkoxy carbonyl group, a carbamoyl group, a mono- or di-substituted C₁ to C₆ alkylcarbamoyl group or a C₁ to C₆ alkylsulfonyl group; and r is 1 or 2.

6. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 2, or a salt thereof, wherein in the ~~general~~-formula (1a), the ring C is represented by the following formula:



wherein R^{2'} is an acetyl group or a methylsulfonyl group; and r is 1 or 2.

7. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 2, or a salt thereof, wherein the ring C in the ~~general formula (1a)~~ is represented by the following formula:



8. (Currently amended) The ~~fused bicyclic pyrimidine derivative~~ compound according to claim 7, or a salt thereof, wherein in the ~~general formula (1a)~~ above, n is 3.

9. (Currently amended) The compound according to claim 1, wherein the compound represented by the ~~general formula (1)~~ is 9-(4-acetylpiperazine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

10. (Currently amended) The compound according to claim 1, wherein the compound represented by the ~~general formula (1)~~ is 5-[3,5-bis(trifluoromethyl)benzyl]-9-(1,1-dioxothiomorpholine-4-yl)-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

11. (Currently amended) The compound according to claim 1, wherein the compound represented by the ~~general formula (1)~~ is 9-(4-acetylhomopiperazine-1-yl)-5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

12. (Currently amended) The compound according to claim 1, wherein the compound represented by the ~~general formula (1)~~ is 5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-9-(4-methylpiperazine-1-yl)-6-oxo-2,3,4,5-tetrahydro-6H-pyrimido[4,5-b][1,5]oxazocine.

13. (Currently amended) A method of achieving tachykinin receptor antagonist ~~containing as an active ingredient the fused bicyclic pyrimidine derivative~~ activity, which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.
14. (Currently amended) ~~An~~ A method of achieving NK1 receptor antagonist ~~containing as an active ingredient the fused bicyclic pyrimidine derivative~~ activity, which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.
15. (Currently amended) A ~~prophylactic or therapeutic agent for~~ method of preventing or treating dysuria, including defective bladder functions such as increased urinary frequency and incontinence of urine, containing as an active ingredient the fused bicyclic pyrimidine derivative ~~which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.~~
16. (Currently amended) A ~~prophylactic or therapeutic agent for~~ method of preventing or treating disorders of digestive tract such as ulcerative colitis and Crohn's disease, containing as an active ingredient the fused bicyclic pyrimidine derivative ~~which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.~~
17. (Currently amended) A ~~prophylactic or therapeutic agent for~~ method of preventing or treating vomiting induced by exposure to X-ray, chemotherapy, pregnancy, migraine, postoperative pains, decreased gastrointestinal motility, and side effects of drugs, containing as an active ingredient the fused bicyclic pyrimidine derivative ~~which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.~~
18. (Currently amended) A ~~therapeutic agent~~ method ~~for treating conditions, such as asthma, coughing, ache, migraine, tooth pain, and rheumatoid arthritis, containing as~~

~~an active ingredient the fused bicyclic pyrimidine derivative~~ which comprises administering a therapeutically effective amount of a compound according to claim 1, or a salt thereof to a patient in need thereof.

19. (New) A pharmaceutical composition containing a compound according to claim 1 or a salt thereof as active ingredient, and one or more pharmaceutically acceptable adjuvants.